Skip to main content

Rheumatoid Arthritis

      RT @synovialjoints: Interstitial lung disease in RA and PSA in b/tsDMARD treated patients with MTX - there is no increa
      1 year 5 months ago
      Interstitial lung disease in RA and PSA in b/tsDMARD treated patients with MTX - there is no increased risk of developing ILD above the background risk of RA and PsA vs general population Sella Aarrestad Provan Abst#OP0006 @RheumNow https://t.co/yJsrmraeZ5
      RT @AurelieRheumo: Comorbidities and metabolic burden in PsA:
      -Occur EARLY
      -Early PsA pts > multiple comorbidities &
      1 year 5 months ago
      Comorbidities and metabolic burden in PsA: -Occur EARLY -Early PsA pts > multiple comorbidities & > CV morbidity vs. age-matched early RA pts Independent of BMI & obesity Time to address these as part of dis pathogenesis in PsA https://t.co/qOiGHn2eZT OP0066 #EULAR23 @Rheumnow https://t.co/lK7MbeMybO
      RT @AurelieRheumo: New benefit/risk outlook 👀 on ORAL surveillance
      2 subgrps:
      🟢RA w/ no previous Hx of atheroscler
      1 year 5 months ago
      New benefit/risk outlook 👀 on ORAL surveillance 2 subgrps: 🟢RA w/ no previous Hx of atherosclerotic CV dis = TOFA at least as good as TNFi AND risk of MACE is comparable 🛑RA w/ HxASCVD = efficacy TOFA = TNFi AND > risk of MACE https://t.co/VOxNQSoyY4 OP0043 #EULAR23 @Rheumnow https://t.co/m98eSMG03U
      RT @AurelieRheumo: Leiden arthritis clinic:
      1000+ pts w/ RA & high BMI associated w/ < MRI-detected osteitis at d
      1 year 5 months ago
      Leiden arthritis clinic: 1000+ pts w/ RA & high BMI associated w/ < MRI-detected osteitis at dis onset but NOT synovitis RA w/ overweight/obesity 25% < MRI-detected erosive progression at 2 yrs More marked in ACPA+ pts Is leptin the missing link? 🤓 OP0039 #EULAR23 @Rheumnow https://t.co/RRSV9VlRtn
      RT @drdavidliew: Biosimilar vs originator: as switches loom in the US, once again it’s really hard to say we see any d
      1 year 5 months ago
      Biosimilar vs originator: as switches loom in the US, once again it’s really hard to say we see any differences in drug survival for our RA patients These data from forced switching in BC, Canada are just like the others - biosimilars are business as usual. POS0567 #EULAR2023 https://t.co/Ebl1hTM4qE
      RT @Janetbirdope: Ongoing work to #classify #inflammatory #arthritis in Pts using #check #point #inhibitors. A 1st step
      1 year 5 months ago
      Ongoing work to #classify #inflammatory #arthritis in Pts using #check #point #inhibitors. A 1st step to study the etiology of immune changes from these life prolonging medications #EULAR2023 @RheumNow https://t.co/Bv1q8IphqF
      RT @Janetbirdope: Can #machine #learning replace #rheumatologists? OP0190 #EULAR23 #Machine learning can help determine
      1 year 5 months ago
      Can #machine #learning replace #rheumatologists? OP0190 #EULAR23 #Machine learning can help determine who will develop #rheumatoidarthritis in Pts with #arthralgia but the real study could be ask #clinician the #probability of RA and do #AI and see comparative accuracy @RheumNow
      RT @drdavidliew: When does RA get complicated?

      Many things can burden our patients, making their RA difficult to treat
      1 year 5 months ago
      When does RA get complicated? Many things can burden our patients, making their RA difficult to treat #EULAR2023 @RheumNow https://t.co/FM1UCNbmKr